Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ludwig, S; Kalbacher, D; Ben Ali, W; Weimann, J; Adam, M; Duncan, A; Webb, JG; Windecker, S; Orban, M; Giannini, C; Coisne, A; Karam, N; Scotti, A; Sondergaard, L; Adamo, M; Muller, DWM; Butter, C; Denti, P; Melica, B; Regazzoli, D; Garatti, A; Schmidt, T; Andreas, M; Dahle, G; Taramasso, M; Nickenig, G; Dumonteil, N; Walther, T; Flagiello, M; Kempfert, J; Fam, N; Ruge, H; Rudolph, TK; von Ballmoos, MCW; Metra, M; Redwood, S; Granada, JF; Tang, GHL; Latib, A; Lurz, P; von Bardeleben, RS; Modine, T; Hausleiter, J; Conradi, L.
Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis
EUR J HEART FAIL. 2023; 25(3): 399-410. Doi: 10.1002/ejhf.2797
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Andreas Martin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Aims This study aimed to compare outcomes after transcatheter mitral valve replacement (TMVR) and mitral valve transcatheter edge-to-edge repair (M-TEER) for the treatment of secondary mitral regurgitation (SMR). Methods and results The CHOICE-MI registry included 262 patients with SMR treated with TMVR between 2014 and 2022. The EuroSMR registry included 1065 patients with SMR treated with M-TEER between 2014 and 2019. Propensity score (PS) matching was performed for 12 demographic, clinical and echocardiographic parameters. Echocardiographic, functional and clinical outcomes out to 1 year were compared in the matched cohorts. After PS matching, 235 TMVR patients (75.5 years [70.0, 80.0], 60.2% male, EuroSCORE II 6.3% [interquartile range 3.8, 12.4]) were compared to 411 M-TEER patients (76.7 years [70.1, 80.5], 59.0% male, EuroSCORE II 6.7% [3.9, 12.4]). All-cause mortality was 6.8% after TMVR and 3.8% after M-TEER at 30 days (p = 0.11), and 25.8% after TMVR and 18.9% after M-TEER at 1 year (p = 0.056). No differences in mortality after 1 year were found between both groups in a 30-day landmark analysis (TMVR: 20.4%, M-TEER: 15.8%, p = 0.21). Compared to M-TEER, TMVR resulted in more effective mitral regurgitation (MR) reduction (residual MR <= 1+ at discharge for TMVR vs. M-TEER: 95.8% vs. 68.8%, p < 0.001), and superior symptomatic improvement (New York Heart Association class <= II at 1 year: 77.8% vs. 64.3%, p = 0.015). Conclusion In this PS-matched comparison between TMVR and M-TEER in patients with severe SMR, TMVR was associated with superior reduction of MR and superior symptomatic improvement. While post-procedural mortality tended to be higher after TMVR, no significant differences in mortality were found beyond 30 days. [GRAPHICS] .
Find related publications in this database (Keywords): Functional mitral regurgitation; Secondary mitral regurgitation; Transcatheter edge-to-edge repair; Transcatheter mitral valve replacement